Search - tctmd.com

Displaying 361 - 380 of 732

Sort: Relevancy | Date

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presentation ACC 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presenter: Brendan M. Everett

March 12, 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Low-Dose, Three-Drug Polypill TRIUMPHs for Blood Pressure

News Conference News ACC 2018

Low-Dose, Three-Drug Polypill TRIUMPHs for Blood Pressure

March 12, 2018

Mixing Haircuts and Hypertension Rx a ‘Home Run’ for Blood Pressure Control

News Conference News ACC 2018

Mixing Haircuts and Hypertension Rx a ‘Home Run’ for Blood Pressure Control

March 12, 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presentation ACC 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presenter: Diego Ardissino

March 12, 2018

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Presentation ACC 2018

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Presenter: Sony Tuteja

March 12, 2018

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Presentation ACC 2018

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Presenter: Mehdi H. Shishehbor

March 12, 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

March 12, 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticouagulants

Presentation ACC 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Presenter: Steve Deitelzweig

March 12, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Presentation ACC 2018

ARTEMIS: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Presenter: Tracy Wang

March 12, 2018

Dabigatran in Myocardial Injury After Noncardiac Surgery

Presentation ACC 2018

MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery

Presenter: Philip Devereaux

March 12, 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

News Conference News ACC 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

March 12, 2018

High Rate of Amputation and Death after Major Adverse Limb Events (MALE) in Peripheral Artery Disease: Results from COMPASS

Presentation ACC 2018

High Rate of Amputation and Death after Major Adverse Limb Events (MALE) in Peripheral Artery Disease: Results from COMPASS

Presenter: Sonia S. Anand

March 11, 2018

Cost-effectiveness of instantaneous wave-Free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decision-making – Analysis from DEFINE FLAIR

Presentation ACC 2018

Analysis from DEFINE FLAIR Trial

Presenter: Manesh R. Patel

March 11, 2018

One-year Clinical Outcomes of the Bio-engineered COMBO stent: Primary Results from the 3614 All-comer Patients in the COMBO Collaboration

Presentation ACC 2018

One-year Clinical Outcomes of the Bio-engineered COMBO stent: Primary Results from the 3614 All-comer Patients in the COMBO Collaboration

Presenter: Antonio Colombo

March 11, 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.